Covid-19 has impacted most of our deals this year in various ways, both on the buy side and sell side. Currently, a common issue we are facing on smaller middle market deals relates to the treatment of loans received pursuant to the CARES Act Payroll Protection Program (PPP). The PPP, which closed to new loan applications on August 8, 2020:
- Allowed founder-owned businesses to receive a loan to help them to continue to make payroll during the pandemic.
- Was administered through the Small Business Administration (SBA) and amounts distributed through commercial banks.
- Was not provided to sponsor backed businesses.
In this article, Alvarez & Marsal’s Managing Directors, Greg Cibuzar, Chris Howe and David Javdan provide diligence insights on the treatment of PPP loans in transactions.
READ THE FULL ARTICLE HERE.
A Closer Look at the Life Sciences Industry: 2025 Life Sciences Report
December 18, 2025
A&M is pleased to present a copy of our 2025 Health of the Life Sciences Industry Report.
Where AI Meets Financial Impact
December 8, 2025
CFOs are uniquely positioned to lead the charge on value creation, leveraging emerging technologies to unlock deeper insights and optimise business decisions. This article explores the transformative potential of AI for financial impact and strategic decision-making.
M&A commentary: Surge in value of deals
December 3, 2025
The ONS data shows M&A activity Q3 remained low, however, since September we’ve seen an uptick. The market seems to have shrugged off market disruption and restarted in earnest. Mike Trenouth provides comments on the latest data release.
A year of recalibration and resilience
December 2, 2025
Private Equity funds have had to be resilient through rising geopolitical tensions, the shock form US tariffs and several years of subdued deal flow and limited exits. But, as 2025 comes to a close, European private equity is showing signs of stability.
